RxDoctor Payments Data

Paul Lehmitz, MD

Internal Medicine · Salt Lake City, UTNPI 1295841419

Payments from drug & device makers

$420in general payments, 2019–2025

Across 16 payments — averaging $26.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$147
  • Novo Nordisk$76
  • AstraZeneca$70
  • Dexcom, Inc.$37
  • Bayer$30
  • Lilly USA, LLC$29
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$420100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$420 in reported general payments places this provider in the 65th percentile of 496 internal medicine providers in Utah.

See all internal medicine providers in Utah

Medicare billing

Part B allowed, 2024
$150,108
Medicare patients
397
Services billed
1,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide195$216,265
OzempicSemaglutide193$193,986
EliquisApixaban222$117,601
XareltoRivaroxaban97$74,588
FarxigaDapagliflozin Propanediol83$45,051
MyrbetriqMirabegron69$29,166
JardianceEmpagliflozin26$20,557
Tresiba Flextouch U-200Insulin Degludec17$18,477
FycompaPerampanel13$15,571
Combivent RespimatIpratropium/Albuterol Sulfate25$12,636
JanuviaSitagliptin Phosphate20$10,995
LokelmaSodium Zirconium Cyclosilicate13$10,802
GemtesaVibegron14$9,707
Novolog FlexpenInsulin Aspart32$9,134
DapagliflozinDapagliflozin Propanediol17$8,392

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$29$216,265195 claims
Novo NordiskOzempic$76$193,986193 claims
AstraZenecaFarxiga, Lokelma, Symbicort, Brilinta$70$68,678145 claims
MerckJanuvia$17$10,99520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 496 internal medicine providers in Utah.

Other internal medicine in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →